LE WE PMID CA
Histone deacetylase1202Histon Deacetylase

Aids

Anemia (Sickle cell)

Angiogenesis

Arthritis (rheumatoid)

Autophagy

Bone marrow transplantation

Butyrate

CNS (Stroke BASKET)

CoREST

Diabetes mellitus (BASKET)

DNA (Methylation)

DNA (Methyltransferase)

DNA (Transcription factors)

DNA (Transcription)

DNA (Transcriptional co repressors)

DNMT1

Epigenetics

Fibrosis

HDAC1

Heart (Hypertrophy)

Hemoglobin F

HIF1alpha und HIF1 (BASKET)

Histone acetyltransferase

Histone deacetylase

Histone demethylase

Inflammatory bowel diseases

Leukemia (BASKET)

Lymphoma (Hodgkin)

MTA protein family

MTA1

MTA1s

MTA2

MTA3

Multiple sclerosis

Muscle dystrophy

Myeloproliferative syndromes

N CoR

Neurodegeneration

Neuroprotective agents

Nicotinamide mononucleotide adenylyltransferase1

Nicotinamide phosphoribosyltransferase

Nitric oxide NO

NuRD

PCD (Multiple myeloma and other plasma cell dyscrasias)

Protein (Posttranslational modification)

Regulatory T cell

Remodeling

Rpd3 Hda1 protein family

Sin3

SIRT1

Sirtuin

SMRT

Systemic lupus erythematosus

Thalassemia

UHRF1 ICBP90 NP95

Vorinostat ttHDAC

2000  
1
Acetylation of histones and transcription-related factors.
[10839822] Microbiol Mol Biol Rev 64(2): 435-59 (2000)
2007  
2
HDAC inhibitors: a potential new category of anti-tumor agents.
[17976313] Cell Mol Immunol 4(5): 337-43 (2007)
2006  
3
The molecular mechanism of HDAC inhibitors in anticancer effects.
[16978537] Cell Mol Immunol 3(4): 285-90 (2006)
2003  
4
Inhibition of histone deacetylase activity by butyrate.
[12840228] J Nutr 133(7 Suppl): 2485S-2493S (2003)
2007  
5
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
[17325692] Cell Res 17(3): 195-211 (2007)
2006  
6
Histone deacetylase inhibitors: a novel target of anticancer therapy (review).
[16391874] Oncol Rep 15(2): 489-94 (2006)
2008  
7
Histone deacetylase inhibitors as novel anticancer therapeutics.
[19008999] Curr Oncol 15(5): 237-43 (2008)
2008  
8
Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors.
[18483291] Mol Cancer Ther 7(5): 1007-12 (2008)
2007  
9
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
[18094401] Clin Cancer Res 13(24): 7237-42 (2007)
2004  
10
The clinical application of targeting cancer through histone acetylation and hypomethylation.
[15269129] Clin Cancer Res 10(14): 4589-96 (2004)
2006  
11
Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention?
[16267097] Carcinogenesis 27(2): 344-9 (2006)
2007  
12
Histone deacetylase inhibitors: overview and perspectives.
[17951399] Mol Cancer Res 5(10): 981-9 (2007)
2007  
13
The role of histone deacetylases (HDACs) in human cancer.
[19383284] Mol Oncol 1(1): 19-25 (2007)
2008  
14
Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
[18813776] Int J Oncol 33(4): 637-46 (2008)
2010  
15
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.
[20132536] J Hematol Oncol 3(-): 5 (2010)
2009  
16
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
[19486511] J Hematol Oncol 2(-): 22 (2009)
2009  
17
Class IIa histone deacetylases: conducting development and differentiation.
[19412888] Int J Dev Biol 53(2-3): 291-301 (2009)
2009  
18
Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation.
[19412887] Int J Dev Biol 53(2-3): 275-89 (2009)
2000  
19
Histone acetylation modifiers in the pathogenesis of malignant disease.
[11055583] Mol Med 6(8): 623-44 (2000)
2001  
20
Deciphering NAD-dependent deacetylases.
[11336664] Cell 105(2): 161-4 (2001)
1997  
21
What's up and down with histone deacetylation and transcription?
[9150131] Cell 89(3): 325-8 (1997)
1996  
22
Targeting chromatin disruption: Transcription regulators that acetylate histones.
[8601304] Cell 84(6): 817-9 (1996)
1976  
23
[Epidemic of keratokonjunctivitis at the IInd Eye Clinic in Prague during 1974-1975].
[963794] Cesk Oftalmol 32(4): 307-10 (1976)
2002  
24
Dissecting histone deacetylase function.
[12079776] Chem Biol 9(6): 668-70 (2002)
1997  
25
Acetylation of general transcription factors by histone acetyltransferases.
[9285713] Curr Biol 7(9): 689-92 (1997)
1997  
26
Transcriptional control: calling in histone deacetylase.
[9259549] Curr Biol 7(8): R505-7 (1997)
1997  
27
Histone acetyltransferases in control.
[9081669] Curr Biol 7(2): R82-4 (1997)
1997  
28
The origin and utility of histone deacetylases.
[9428625] FEBS Lett 419(2-3): 157-60 (1997)
1993  
29
Histone deacetylase. A key enzyme for the binding of regulatory proteins to chromatin.
[8425601] FEBS Lett 317(3): 175-80 (1993)
2006  
30
Enhanced histone acetylation and transcription: a dynamic perspective.
[16885019] Mol Cell 23(3): 289-96 (2006)
2001  
31
Structure of histone deacetylases: insights into substrate recognition and catalysis.
[11738039] Structure 9(12): 1127-33 (2001)
1990  
32
On the biological role of histone acetylation.
[2405837] Biochem J 265(1): 23-38 (1990)
2004  
33
Histone-deacetylase inhibitors for the treatment of cancer.
[15153801] Cell Cycle 3(6): 779-88 (2004)
2006  
34
Control of cardiac growth by histone acetylation/deacetylation.
[16397154] Circ Res 98(1): 15-24 (2006)
2008  
35
The role of histone deacetylases in prostate cancer.
[19029799] Epigenetics 3(6): 300-9 (2008)
2008  
36
HDACs and HDAC inhibitors in colon cancer.
[18326939] Epigenetics 3(1): 28-37 (2008)
2006  
37
Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer.
[17965606] Epigenetics 1(3): 121-6 (2006)
2006  
38
Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
[17998807] Epigenetics 1(2): 67-75 (2006)
2006  
39
Histone deacetylase inhibitors for cancer therapy.
[17998811] Epigenetics 1(1): 14-23 (2006)
2005  
40
Histone acetylation and deacetylation: importance in inflammatory lung diseases.
[15738302] Eur Respir J 25(3): 552-63 (2005)
2001  
41
Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin.
[11257101] Hum Mol Genet 10(7): 693-8 (2001)
2006  
42
Simple histone acetylation plays a complex role in the regulation of gene expression.
[16980317] Brief Funct Genomic Proteomic 5(3): 190-208 (2006)
2006  
43
Epigenetic regulators and histone modification.
[16951415] Brief Funct Genomic Proteomic 5(3): 222-7 (2006)
2006  
44
1991  
45
Histone acetylation and control of gene expression.
[1757496] J Cell Sci 99 ( Pt 1)(-): 13-20 (1991)
2003  
46
Histone deacetylase inhibitors in cancer therapy.
[12673114] Cancer Biol Ther 2(1): 30-7 (2003)
2008  
47
Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
[18983693] Arthritis Res Ther 10(5): 226 (2008)
2011  
48
Potential non-oncological applications of histone deacetylase inhibitors.
[22046487] Am J Transl Res 3(5): 454-67 (2011)
2011  
49
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
[21416059] Am J Transl Res 3(2): 166-79 (2011)
2010  
50
SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions.
[19879981] Biochim Biophys Acta 1804(8): 1666-75 (2010)
2007  
51
Roles of dynamic and reversible histone acetylation in plant development and polyploidy.
[17556080] Biochim Biophys Acta 1769(5-6): 295-307 (2007)
2009  
52
Nitric oxide-mediated epigenetic mechanisms in developing neurons.
[19221483] Cell Cycle 8(5): 725-30 (2009)
2010  
53
Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
[20133912] Circ Res 106(2): 272-84 (2010)
2006  
54
Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.
[16883049] J Biomed Biotechnol 2006(2): 13474 (2006)
2011  
55
Autophagic and apoptotic effects of HDAC inhibitors on cancer cells.
[21629704] J Biomed Biotechnol 2011(-): 830260 (2011)
2011  
56
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
[21765634] J Biomed Biotechnol 2011(-): 514261 (2011)
2011  
57
Beyond histone and deacetylase: an overview of cytoplasmic histone deacetylases and their nonhistone substrates.
[21234400] J Biomed Biotechnol 2011(-): 146493 (2011)
2011  
58
The role of HDACs inhibitors in childhood and adolescence acute leukemias.
[21318168] J Biomed Biotechnol 2011(-): 148046 (2011)
2011  
59
Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.
[21151670] J Biomed Biotechnol 2011(-): 197946 (2011)
2011  
60
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.
[21188171] J Biomed Biotechnol 2011(-): 475641 (2011)
2011  
61
Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2.
[21197454] J Biomed Biotechnol 2011(-): 690848 (2011)
2011  
62
Physiological roles of class I HDAC complex and histone demethylase.
[21049000] J Biomed Biotechnol 2011(-): 129383 (2011)
2011  
63
Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
[20981265] J Biomed Biotechnol 2011(-): 315939 (2011)
2011  
64
Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
[21151616] J Biomed Biotechnol 2011(-): 928326 (2011)
2011  
65
2002  
66
Biological roles and mechanistic actions of co-repressor complexes.
[11865025] J Cell Sci 115(Pt 4): 689-98 (2002)
2009  
67
Epigenetic histone acetylation modifiers in vascular remodelling: new targets for therapy in cardiovascular disease.
[19147603] Eur Heart J 30(3): 266-77 (2009)
2009  
68
Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke.
[19478231] Stroke 40(8): 2899-905 (2009)
2008  
69
Isoform-selective histone deacetylase inhibitors.
[18568166] Chem Soc Rev 37(7): 1402-13 (2008)
2003  
70
Regulating histone acetyltransferases and deacetylases.
[14528264] EMBO Rep 4(10): 944-7 (2003)
2008  
71
Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia.
[18617435] Int J Biochem Cell Biol 40(11): 2341-7 (2008)
2008  
72
Eloquent silence: developmental functions of Class I histone deacetylases.
[18929655] Curr Opin Genet Dev 18(5): 404-10 (2008)
2009  
73
Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.
[19509170] Clin Cancer Res 15(12): 3947-57 (2009)
2009  
74
Rational combinations using HDAC inhibitors.
[19509171] Clin Cancer Res 15(12): 3970-7 (2009)
2009  
75
Clinical studies of histone deacetylase inhibitors.
[19509172] Clin Cancer Res 15(12): 3958-69 (2009)
2006  
76
Targeting epigenetic abnormalities with histone deacetylase inhibitors.
[16826577] Cancer 107(4): 832-40 (2006)
2008  
77
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
[18728657] Br J Cancer 99(5): 689-94 (2008)
2003  
78
Histone deacetylases (HDACs): characterization of the classical HDAC family.
[12429021] Biochem J 370(Pt 3): 737-49 (2003)
2008  
79
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men.
[18292778] Nat Rev Mol Cell Biol 9(3): 206-18 (2008)
2008  
80
Class IIA HDACs in the regulation of neurodegeneration.
[17981613] Front Biosci 13(-): 1072-82 (2008)
2011  
81
Targeting inflammation in heart failure with histone deacetylase inhibitors.
[21267510] Mol Med 17(5-6): 434-41 (2011)
2011  
82
Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries.
[21274503] Mol Med 17(5-6): 448-56 (2011)
2011  
83
Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.
[21274504] Mol Med 17(5-6): 378-90 (2011)
2011  
84
HDAC inhibition and graft versus host disease.
[21298214] Mol Med 17(5-6): 404-16 (2011)
2011  
85
Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.
[21308150] Mol Med 17(5-6): 457-65 (2011)
2011  
86
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
[21308151] Mol Med 17(5-6): 397-403 (2011)
2011  
87
HDAC inhibition in lupus models.
[21327298] Mol Med 17(5-6): 417-25 (2011)
2011  
88
Inhibition of histone deacetylases in inflammatory bowel diseases.
[21365125] Mol Med 17(5-6): 426-33 (2011)
2011  
89
The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.
[21373721] Mol Med 17(5-6): 442-7 (2011)
2011  
90
Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.
[21424110] Mol Med 17(5-6): 466-72 (2011)
2009  
91
Targeting tumor angiogenesis with histone deacetylase inhibitors.
[19111391] Cancer Lett 280(2): 145-53 (2009)
2009  
92
Multiple roles of HDAC inhibition in neurodegenerative conditions.
[19775759] Trends Neurosci 32(11): 591-601 (2009)
2005  
93
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
[15955865] Mol Pharmacol 68(4): 917-32 (2005)
2010  
94
Epigenetic therapy: targeting histones and their modifications in human disease.
[21426003] Future Med Chem 2(4): 543-8 (2010)
2009  
95
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.
[19855427] Nat Rev Drug Discov 8(12): 969-81 (2009)
2010  
96
Macrocyclic histone deacetylase inhibitors.
[20536416] Curr Top Med Chem 10(14): 1423-40 (2010)
2009  
97
Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.
[19355989] Curr Top Med Chem 9(3): 241-56 (2009)
2010  
98
HDAC inhibitors and neurodegeneration: at the edge between protection and damage.
[20123018] Pharmacol Res 62(1): 11-7 (2010)
2009  
99
Putting the 'HAT' back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions.
[19388875] Expert Opin Investig Drugs 18(5): 573-84 (2009)
2009  
100
Explorative study on isoform-selective histone deacetylase inhibitors.
[19721249] Chem Pharm Bull (Tokyo) 57(9): 897-906 (2009)
2010  
101
Role of HDAC1 in senescence, aging, and cancer.
[19818845] Exp Gerontol 45(4): 279-85 (2010)
2010  
102
Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies.
[20831615] J Neurochem 115(4): 806-13 (2010)
2003  
103
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
[12542981] J Biochem Mol Biol 36(1): 110-9 (2003)
2009  
104
Histone deacetylase inhibitors: Potential in cancer therapy.
[19459166] J Cell Biochem 107(4): 600-8 (2009)
2008  
105
A work in progress: the clinical development of histone deacetylase inhibitors.
[18487953] Epigenetics 3(3): 164-71 (2008)
2011  
106
Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.
[21496237] J Exp Clin Cancer Res 30(-): 41 (2011)
2006  
107
Dietary agents as histone deacetylase inhibitors.
[16652377] Mol Carcinog 45(6): 443-6 (2006)
2007  
108
MTA family of coregulators in nuclear receptor biology and pathology.
[18174918] Nucl Recept Signal 5(-): e010 (2007)
2010  
109
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.
[21258646] Clin Epigenetics 1(3-4): 117-136 (2010)
2010  
110
Histone deacetylase inhibitors in the therapy of cancer: much to learn.
[22122077] Epigenomics 2(6): 723-5 (2010)
2010  
111
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
[21161327] Invest New Drugs 28 Suppl 1(): S3-20 (2010)
2010  
112
Histone deacetylase inhibitors in Hodgkin lymphoma.
[21127943] Invest New Drugs 28 Suppl 1(): S21-7 (2010)
2010  
113
Deactylase inhibition in myeloproliferative neoplasms.
[21127942] Invest New Drugs 28 Suppl 1(): S50-7 (2010)
2010  
114
The DAC system and associations with multiple myeloma.
[21120582] Invest New Drugs 28 Suppl 1(): S28-35 (2010)
PMC   
115
Histone deacetylase signaling in cardioprotection.
[24310814] Cell Mol Life Sci 71(9):1673-90 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



Search PubMed and many other databases on the combined search terms

GG: histone deacylase
GG: hdac

  • Histon Deacetylase

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia